The DOI matches its Crossref record; 112 of the 112 references it cites were found in a registry or an index.
The molecular mechanisms of chemoresistance in cancers
Open accessAbstract
// Hua-Chuan Zheng 1 1 Department of Experimental Oncology and Animal Center, Shengjing Hospital of China Medical University, Shenyang 110004, China Correspondence to: Hua-Chuan Zheng, email: zheng_huachuan@hotmail.com Keywords: cancer, chemoresistance, molecular mechanisms, chemotherapy Received: March 31, 2017 Accepted: June 24, 2017 Published: July 06, 2017 ABSTRACT Overcoming intrinsic and acquired drug resistance is a major challenge in treating cancer patients because chemoresistance causes recurrence, cancer dissemination and death. This review summarizes numerous molecular aspects of multi-resistance, including transporter pumps, oncogenes (EGFR, PI3K/Akt, Erk and NF-κB), tumor suppressor gene (p53), mitochondrial alteration, DNA repair, autophagy, epithelial-mesenchymal transition (EMT), cancer stemness, and exosome. The chemoresistance-related proteins are localized to extracellular ligand, membrane receptor, cytosolic signal messenger, and nuclear transcription factors for various events, including proliferation, apoptosis, EMT, autophagy and exosome. Their cross-talk frequently appears, such as the regulatory effects of EGFR-Akt-NF-κB signal pathway on the transcription of Bcl-2, Bcl-xL and survivin or EMT-related stemness. It is essential for the realization of the target, individualized and combine therapy to clarify these molecular mechanisms, explore the therapy target, screen chemosensitive population, and determine the efficacy of chemoreagents by cell culture and orthotopic model.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
4 retracted
Zhang, J., Xu, Y., Gao, Y., Chen, C., Zheng, Z.-S., Yun, M., Weng, H.-W., Xie, D., & Ye, S. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0586-y · Cited by 88
RetractedMiR-200b regulates autophagy associated with chemoresistance in human lung adenocarcinoma
Pan, B., Feng, B., Chen, Y., Huang, G., Wang, R. Y., Chen, L., & Song, H. (2015) · Oncotarget · doi:10.18632/oncotarget.5352 · Cited by 74
RetractedYu, X., Du, J., Fan, Y.-J., Liu, F., Cao, L., Liang, N., Xu, D., & Zhang, J. (2016) · Oncotarget · doi:10.18632/oncotarget.12718 · Cited by 41
RetractedNANOG regulates epithelial–mesenchymal transition and chemoresistance in ovarian cancer
Qin, S., Li, Y., Cao, X., Du, J., & Huang, X. (2016) · Bioscience Reports · doi:10.1042/bsr20160247 · Cited by 37
RetractedOverexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line
Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V., & Deeley, R. G. (1992) · Science · doi:10.1126/science.1360704 · Cited by 3,037
A multidrug resistance transporter from human MCF-7 breast cancer cells
Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T., Gao, Y., Rishi, A. K., & Ross, D. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15665 · Cited by 2,322
NF-kB in development and progression of human cancer
Dolcet, X., Llobet, D., Pallares, J., & Matias-Guiu, X. (2005) · Virchows Archiv · doi:10.1007/s00428-005-1264-9 · Cited by 1,169
Aggarwal, B. B., Vijayalekshmi, R. V., & Sung, B. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0149 · Cited by 795
Cancer-associated fibroblast exosomes regulate survival and proliferation of pancreatic cancer cells
Richards, K. E., Zeleniak, A. E., Fishel, M. L., Wu, J., Littlepage, L. E., & Hill, R. (2017) · Oncogene · doi:10.1038/onc.2016.353 · Cited by 735
Wei, Y., Zou, Z., Becker, N., Anderson, M., Sumpter, R., Xiao, G., Kinch, L., Koduru, P., Christudass, C. S., Veltri, R. W., et al. (2013) · Cell · doi:10.1016/j.cell.2013.08.015 · Cited by 505
Cited by
5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future
Vodenkova, S., Buchler, T., Cervena, K., Veskrnova, V., Vodicka, P., & Vymetalkova, V. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107447 · Cited by 956
The multi-factorial nature of clinical multidrug resistance in cancer
Assaraf, Y. G., Brozovic, A., Gonçalves, A. C., Jurkovicova, D., Linē, A., Machuqueiro, M., Saponara, S., Sarmento-Ribeiro, A. B., Xavier, C. P. R., & Vasconcelos, M. H. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100645 · Cited by 528
Multidrug Resistance (MDR): A Widespread Phenomenon in Pharmacological Therapies
Catalano, A., Iacopetta, D., Ceramella, J., Scumaci, D., Giuzio, F., Saturnino, C., Aquaro, S., Rosano, C., & Sinicropi, M. S. (2022) · Molecules · doi:10.3390/molecules27030616 · Cited by 450
The Akt pathway in oncology therapy and beyond (Review)
Nitulescu, G., Van De Venter, M., Nitulescu, G., Ungurianu, A., Juzenas, P., Peng, Q., Olaru, O., Grădinaru, D., Tsatsakis, A., Tsoukalas, D., et al. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4597 · Cited by 328
Molecular mechanisms and therapeutic strategies in overcoming chemotherapy resistance in cancer
Gu, Y., Yang, R., Zhang, Y., Guo, M., Takehiro, K., Zhan, M., Yang, L., & Wang, H. (2025) · Molecular Biomedicine · doi:10.1186/s43556-024-00239-2 · Cited by 184
Metadata
- Authors
- Zheng, H.-C.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2017-07-06
- Volume
- 8
- Issue
- 35
- Pages
- 59950-59964
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2729738977
- Cited by
- 624
- References
- 112
- FWCI
- 24.23
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The molecular mechanisms of chemoresistance in cancers. https://app.cochat.ai/papers/10.18632/oncotarget.19048
- The paper
- Zheng, H.-C. (2017). The molecular mechanisms of chemoresistance in cancers. Oncotarget. https://doi.org/10.18632/oncotarget.19048
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
